{
    "clinical_study": {
        "@rank": "131039", 
        "acronym": "TREMODI", 
        "arm_group": {
            "arm_group_label": "Prostate Cancer patients"
        }, 
        "brief_summary": {
            "textblock": "Tremodi is an observational, non-interventional, prospective, open-label, non-comparative\n      study that will collect real life data of a treatment with Depo-Eligard\u00ae in 3 different\n      administrations in male prostate cancer patients.\n\n      Once the examining physician has decided on the therapeutic approach and if the selection\n      criteria are fulfilled, he will propose the patient to participate in the study. An informed\n      consent form will be collected for all participants in the study.\n\n      There are 2 possible study visits that coincide with a routine consultation, namely visit 1\n      (inclusion visit) and visit 2 (end of study visit). On both visits, Adverse Drug Reactions\n      (adverse event caused by Depo-Eligard\u00ae) are collected and the patient will be asked to\n      complete a Quality Of Life questionnaire (EORTC QLQ-C30). At visit 2, the examining\n      physician will give a global evaluation of the treatment with Depo-Eligard\u00ae and assesses the\n      treatment benefit of the patient.\n\n      Testosterone and Prostate Specific Antigen (PSA) blood values are collected during both\n      visits, if available."
        }, 
        "brief_title": "Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard\u00ae 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients having been prescribed Depo-Eligard\u00ae 7.5 mg - 22.5 mg - 45 mg in accordance\n             with the terms of the marketing authorization."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Consultation at urology department"
            }
        }, 
        "enrollment": {
            "#text": "259", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01793077", 
            "org_study_id": "BE-11-EGD-04"
        }, 
        "intervention": {
            "arm_group_label": "Prostate Cancer patients", 
            "description": "Subcutaneous", 
            "intervention_name": "Depo-Eligard\u00ae", 
            "intervention_type": "Drug", 
            "other_name": "Leuprolide Acetate"
        }, 
        "intervention_browse": {
            "mesh_term": "Leuprolide"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Prostate Cancer", 
            "Phase 4", 
            "Data collection", 
            "Observational", 
            "Depo-Eligard", 
            "Prospective", 
            "Non-interventional", 
            "Treatment"
        ], 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "state": "Antwerp", 
                        "zip": "2200"
                    }, 
                    "name": "Site: 4"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "state": "Antwerp", 
                        "zip": "2018"
                    }, 
                    "name": "Site: 5"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "state": "Antwerp", 
                        "zip": "2018"
                    }, 
                    "name": "Site: 8"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "state": "Antwerp", 
                        "zip": "2018"
                    }, 
                    "name": "Site: 9"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Antwerpen", 
                        "country": "Belgium", 
                        "state": "Antwerp", 
                        "zip": "2020"
                    }, 
                    "name": "Site: 14"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Merksem", 
                        "country": "Belgium", 
                        "state": "Antwerp", 
                        "zip": "2170"
                    }, 
                    "name": "Site: 33"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Turnhout", 
                        "country": "Belgium", 
                        "state": "Antwerp", 
                        "zip": "2300"
                    }, 
                    "name": "Site: 1"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brussel", 
                        "country": "Belgium", 
                        "state": "Brussels Capital Region", 
                        "zip": "1090"
                    }, 
                    "name": "Site: 13"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bruxelles", 
                        "country": "Belgium", 
                        "state": "Brussels Capital Region", 
                        "zip": "1030"
                    }, 
                    "name": "Site: 23"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Uccle", 
                        "country": "Belgium", 
                        "state": "Brussels Capital Region", 
                        "zip": "1180"
                    }, 
                    "name": "Site: 24"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Aalst", 
                        "country": "Belgium", 
                        "state": "East Flanders", 
                        "zip": "9300"
                    }, 
                    "name": "Site: 32"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dendermonde", 
                        "country": "Belgium", 
                        "state": "East Flanders", 
                        "zip": "9200"
                    }, 
                    "name": "Site: 34"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gent", 
                        "country": "Belgium", 
                        "state": "East Flanders", 
                        "zip": "9000"
                    }, 
                    "name": "Site: 11"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oudenaarde", 
                        "country": "Belgium", 
                        "state": "East Flanders", 
                        "zip": "9700"
                    }, 
                    "name": "Site: 17"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tienen", 
                        "country": "Belgium", 
                        "state": "Flemish Brabant", 
                        "zip": "3300"
                    }, 
                    "name": "Site: 18"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Louvi\u00e8re", 
                        "country": "Belgium", 
                        "state": "Hainaut", 
                        "zip": "7100"
                    }, 
                    "name": "Site: 39"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sint Truiden", 
                        "country": "Belgium", 
                        "state": "Limburg", 
                        "zip": "3800"
                    }, 
                    "name": "Site: 37"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lasne Chapelle Saint Lambert", 
                        "country": "Belgium", 
                        "state": "Walloon Brabant", 
                        "zip": "1380"
                    }, 
                    "name": "Site: 26"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ieper", 
                        "country": "Belgium", 
                        "state": "West Flanders", 
                        "zip": "8900"
                    }, 
                    "name": "Site: 21"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Izegem", 
                        "country": "Belgium", 
                        "state": "West Flanders", 
                        "zip": "8870"
                    }, 
                    "name": "Site: 20"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kortijk", 
                        "country": "Belgium", 
                        "state": "West Flanders", 
                        "zip": "8500"
                    }, 
                    "name": "Site: 25"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oostende", 
                        "country": "Belgium", 
                        "state": "West Flanders", 
                        "zip": "8400"
                    }, 
                    "name": "Site: 31"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Li\u00e8ge", 
                        "country": "Belgium", 
                        "zip": "4000"
                    }, 
                    "name": "Site: 38"
                }
            }
        ], 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Phase IV, Non-interventional, Prospective, Open Label, Non Comparative Real Life Data Collection of Depo-Eligard\u00ae 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients", 
        "overall_official": {
            "affiliation": "Astellas Pharma Europe B.V.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Belgium: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Evaluation of tolerability of treatment on a 4 point scale", 
            "safety_issue": "No", 
            "time_frame": "Last Visit (after at least 180 days of treatment)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01793077"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Occurrence of Adverse Drug Reactions", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Last Visit (after at least 180 days of treatment)"
            }, 
            {
                "measure": "Investigator satisfaction with treatment", 
                "safety_issue": "No", 
                "time_frame": "Last Visit (after at least 180 days of treatment)"
            }, 
            {
                "measure": "Overall patient's assessment of treatment benefit", 
                "safety_issue": "No", 
                "time_frame": "Last Visit (after at least 180 days of treatment)"
            }, 
            {
                "description": "European Organization for Research and Treatment of Cancer, Quality of Life Questionnaire-C 30 (EORTC-QLQ-C30)", 
                "measure": "Changes in quality of life of subjects as measured by EORTC QLQ-C30", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Last Visit (after at least 180 days of treatment)"
            }, 
            {
                "measure": "Frequency of use of dosing schedules of Depo-Eligard\u00ae  and the reasons for selecting a schedule", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Last Visit (after at least 180 days of treatment)"
            }, 
            {
                "description": "(1) Changes in PSA and testosterone levels if available, (2) Change in disease symptoms and (3) Objective disease response", 
                "measure": "Efficacy of treatment", 
                "safety_issue": "No", 
                "time_frame": "Day 1 and Last Visit (after at least 180 days of treatment)"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "collaborator": {
                "agency": "Veeda Clinical Research", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Astellas Pharma Europe B.V.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2011", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "January 2014"
    }
}